Full-Time
Surgical Consumable Lead
Consumable Sales, Trade & Government Accounts
Posted on 10/31/2025
Zeiss
1,001-5,000 employees
Supplies lithography optics for semiconductor manufacturing
No salary listed
Ahmedabad, Gujarat, India
In Person
 Sales & Account Management (5) |
|---|
| , , , , |
- Consumable Sales Experience
- Science Graduate
- Surgical Consumable Lead responsible for Consumable Business Growth in Gujrat & MP market. He will responsible for Trade; Govt and SG &P Accounts.
- Preferably MBA
Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Simplify's Take
What believers are saying
- ASML's 24.9% stake secures long-term exclusive optics partnership.
- Over 8,349 employees across nine global sites drive R&D innovation.
- SFS's MultiSEM with 91 beams accelerates 2D process optimization.
What critics are saying
- ASML pressures Zeiss for price cuts, eroding margins in 6-12 months.
- Intel's 2025 High-NA EUV halt slashes Zeiss revenue by 20%.
- SMEE's Q1 2026 7nm optics capture 30% of Zeiss Asia revenue.
What makes Zeiss unique
- Exclusive supplier of optical systems for ASML's EUV lithography machines.
- Three units: SMO for DUV/EUV/High-NA-EUV optics, SMS for photomasks, SFS for inspection.
- Advances High-NA-EUV enabling three times more microchip structures.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Company News
ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.
ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.
ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.
Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.
Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.